Multicenter study suggests early rasburicase prevents kidney failure and death in tumor lysis syndrome

Tumor lysis syndrome (TLS) is a severe, life-threatening condition that arises when rapidly dying cancer cells release substances like uric acid into the blood, potentially damaging the kidneys and leading to serious complications. Despite rasburicase being widely used to treat TLS for over two decades due to its ability to rapidly reduce uric acid levels, a lack of rigorous studies has hindered a clear understanding of its impact on patient outcomes such as preventing dialysis or death.

To fill this gap, researchers conducted a multicenter study analyzing data from over 1,276 adult TLS patients treated at 36 U.S. hospitals between 2014 and 2023. Utilizing an emulated target trial design, the study compared outcomes between patients who received rasburicase within 12 hours of TLS onset and those who received it later or not at all.

Led by senior author Dr. David Leaf from Mass General Brigham, the findings revealed that early rasburicase treatment was associated with a one-third reduction in the risk of dialysis or in-hospital death compared to delayed or no treatment.

The researchers estimated that providing early rasburicase treatment could prevent one case of dialysis or death for every 11 patients. This advantage was particularly pronounced in patients who were already the most critically ill, including those with moderate-to-severe kidney injury at the time TLS developed. Early rasburicase treatment was also linked to lower 90-day mortality rates and a quicker return to cancer therapy.

The greatest benefits were observed in the sickest patients, highlighting the importance of timely rasburicase administration in managing TLS.